Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

Inclusion Criteria: * Subject is at least 18 and not older than 55 years of age on the day of the first dosing. * Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to the first dosing. * Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included. * Subject is able and willing to sign the Informed Consent Form prior to screening evaluations. * Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to the first dose. * Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement. Exclusion Criteria: * Documented history of sensitivity/idiosyncrasy to medicinal products or excipients. * Positive HIV test. * Positive hepatitis B or C test. * Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the first dose) or breast-feeding female. * Therapy with any drug (for two weeks preceding dosing), except for paracetamol. * Subjects with an ECG with QTc interval greater than 450 ms for men, and greater than 470 ms for women at screening. * Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabetes mellitus), coagulation disorders. * Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. * History of or current abuse of drugs, alcohol or solvents. * Inability to understand the nature and extent of the trial and the procedures required. * Participation in a drug trial within 60 days prior to the first dose. * Donation of blood within 60 days prior to the first dose. * Febrile illness within 3 days before the first dose